SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...

Data on valve durability with transcatheter aortic valve replacement are reassuring at 7 years, with implications for ...

Edwards Lifesciences gains attention after fresh valve data as structural heart devices, valuation debate, and healthcare ...

In mostly women with small aortic annuli, self-expanding valves maintained superior hemodynamics and far lower valve ...

“TAVR with the Sapien 3 platform demonstrated comparable 7-year durability to surgery, supporting its use as a treatment option in lifetime management of low-risk patients with symptomatic severe AS,” ...

A novel nickel-free, low-profile TAVI valve shows promise in treating severe aortic stenosis, according to first-in-human ...

NEW YORK--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new data presented at New York Valves 2026, the annual conference organized by the Cardiovascular Research Foundation, which ...

The proposed Medicare coverage change could help Edwards Lifesciences gain market share from Medtronic and Boston Scientific, an analyst said.

Kauvery Hospital, Alwarpet, has successfully treated two failing heart valves in a patient without repeat open-heart surgery, ...

On Monday, the Centers for Medicare & Medicaid Services (CMS) proposed removing the coverage with evidence development (CED) requirement for Transcatheter Aortic Valve Replacement (TAVR) in patients ...

Kauvery Hospital, Alwarpet, has successfully treated two failing heart valves in a patient without repeat open-heart surgery, ...